February 15, 2022: NCHR testifies against the opioid, tramadol, administered by IV to the FDA Advisory Committee.
Read More »On Medical Treatments & Products
Statement by Dr. Diana Zuckerman on Sintilimab at FDA Advisory Committee on Oncologic Drugs
February 10, 2022: NCHR president Dr. Diana Zuckerman testifies to the FDA Advisory Committee on Oncologic Drugs on Sintilimab.
Read More »NCHR’s Comments on Prediabetes and Type 2 Diabetes Screening for Children and Adolescents
January 18, 2022: We support the “I” recommendation against screening for either prediabetes or type 2 diabetes in asymptomatic children aged 18 years or younger.
Read More »Statement of Dr. Diana Zuckerman Regarding the January 11, 2022 CMS Decision about Aduhelm
January 11, 2022: Dr. Diana Zuckerman, president of NCHR, speaks in favor of CMS decision to limit coverage of the Alzheimer’s drug, Aduhelm.
Read More »NCHR’s Testimony to FDA on Bardoxolone for Kidney Failure from Alport Syndrome
December 8, 2021: We agree with FDA scientists that bardoxolone does not demonstrate effectiveness at slowing the loss of kidney function and reducing the risk of progression to kidney failure, which are the outcomes that matter most to patients.
Read More »